CYCN (cyclerion.com) Net Income

CYCN (Cyclerion Therapeutics) - company brandmark

Cyclerion Therapeutics' net income metric demonstrates the impact of liquidity on capital, where -0.01 serves as the final level marker. Strict small-molecule patents and FDA oversight provide a defensive moat for the business. The model scales through contract manufacturing of CNS drugs, converting costs into margins. The reputation of Cyclerion Therapeutics is based on the deep study of cerebral vessel biology for the therapy of rare pathologies.

Net Profit: Cyclerion (CYCN) for 07/04/2022 - 09/09/2026

Financial and market metric breakdowns for cyclerion.com (CYCN)

- stock value and consensus price forecast:
Market Price Cyclerion Therapeutics, Inc.|CYCN - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Cyclerion Therapeutics|CYCN - Real Price to Acquire Entire Company
- company book value details:
Net Asset Value per Share Cyclerion Therapeutics|CYCN - Book Capitalization|Market Cap to Net Assets Ratio cyclerion.com|CYCN - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Cyclerion Therapeutics|CYCN - Long-Term Debt to Capital|Current Liabilities to Capital Cyclerion Therapeutics, Inc.|CYCN - Company Debts|Debt to Net Assets Ratio Cyclerion Therapeutics|CYCN - Company Long-Term Debts|Short-Term Debt Volume Cyclerion Therapeutics|Immediate Liquidity cyclerion.com
- company profitability and valuation multiples indicators:
CYCN - Company Net Income
Basic company analysis:Cyclerion (CYCN)
Finished products of Cyclerion Therapeutics

To minimize investment risks, it is necessary to isolate one-time gains from sustainable operating cash flow. This indicator reflects the market consensus for daily earnings per share, and an analysis of Cyclerion Therapeutics (CYCN) marginal income allows for the identification of hidden reporting lags, which is critical for assessing the monetization of patented guanylate cyclase stimulator formulas within long-term CNS disease treatment programs.

Direct competitors

Company Net Income Biogen Idec (BIIB)|NBIX (Neurocrine Biosciences) - Net Profit|Net Income regencellbioscience.com (RGC)|Net Income AXSM (Axsome Therapeutics, Inc.)|ACAD - Company Net Income|Net Profit XENE (Xenon Pharmaceuticals Inc)|VKTX - Net Income|SUPN - Company Net Income|CPRX: Company Net Income|DNLI: Net Profit|Company Net Income Harmony Biosciences Inc (HRMY)|Company Net Income Biohaven Pharmaceutical|AMLX: Final Profit|Net Profit TRVI|Net Financial Result praxismedicines.com|Company Net Income Anavex Life Sciences Corp. AVXL|CeriBell Inc (CBLL) - Company Net Income|PRTA - Company Net Income|ALEC (Alector, Inc.) - Company Profit|ANNX (Annexon, Inc.) - Net Income|Omeros - Final Profit|Net Income NGNE|ACIU (AC Immune S.A.) - Profit After Payment of Taxes|Net Profit VYGR|NMRA (Neumora Corp) - Final Profit|Net Profit SCLX (Scilex Holding Company)|tevogen.com (TVGN) - Company Net Income|ACOG - Company Net Income|Final Profit CGTX (cogrx.com)|IKT: Net Profit|Cassava Pharma (SAVA) - Net Profit|Company Net Income Assertio Holdings|Coya - Profit After Tax|Net Profit VTGN|OVID - Company Net Income|Acumen Pharma - Net Income|Net Profit CervoMed Corporation CRVO|ATHE: Net Income|Clene Inc. - Profit After Payment of Taxes|PEPG: Net Profit|JUNS - Net Financial Result|RLMD (Relmada) - Net Profit|Net Income Annovis Bio Corporation (ANVS)|Company Net Income Grace Therapeutics, Inc. (GRCE)|Net Financial Result fireflyneuro.com|Net Profit KLTO (Klotho Neurosciences)|NRSN - Net Income|RVPH: Net Income|Company Net Income MetaVia Inc|NRXS: Net Profit|Net Income Helius Medical Technologies|Company Net Income Passage Bio Inc.|Company Profit NEUP (Neuphoria)|Company Net Income Minerva Neurosciences Corp (NERV)|Athira Pharma Corp - Company Profit|Net Profit ADXN (Addex Therapeutics)|Alzamend Neuro Inc. (ALZN) - Company Net Income|PTIX: Net Income|KTTA - Net Profit|cortigent.com (CRGT) - Company Net Income|Avenue Therapeutics Inc - Final Profit|Company Net Income Brainstorm Cell|Company Net Income caratherapeutics.com CARA|Net Profit CHRO|Net Income eliemtx.com ELYM|Intra-Cellular Therapies, Inc. - Net Income|Longboard (LBPH) - Company Net Income|Marinus Pharmaceuticals - Net Profit|nkgenbiotech.com (NKGN) - Net Income|NeuroBo Pharmaceuticals, Inc. (NRBO) - Company Net Income|SAGE (Sage Therapeutics Inc.) - Company Net Income|SNPX (Neurotrope) - Net Profit|Company Net Income Trevena Inc TRVN|Company Net Income Vigil Neuroscience (VIGL)|WENA (Anew Medical Inc.) - Final Profit|Net Profit CERE (Cerevel Therapeutics, Inc.)